OCLG Oncologix Tech Inc (CE)

ALEXANDRIA, LA--(Marketwired - Jan 14, 2014) - Oncologix Tech Inc. (OTCQB: OCLG) announced today that it has retained The Eversull Group to manage its Financial Public Relations, Investor Relations and Shareholder Consulting Services.

The Eversull Group was established in 1997 and is based in Frisco, Texas, a suburb of Dallas. The Eversull Group has been successful in obtaining national and international media coverage for its public clients and in introducing individual and institutional investors. The Eversull Group has also been successful in assisting OTC companies seeking to list on primary stock exchanges.

Wayne Erwin, Chairman and CEO of Oncologix, stated, "The Eversull Group is a highly regarded public relations firm with deep experience in providing information and communications to public shareholders and potential investors. As we deliver on the OCLG strategy this year, we will need their high-caliber organization to assist in disseminating our corporate information as it occurs. We look forward to their efforts in helping us grow."

Jack Eversull, President of The Eversull Group, remarked, "Oncologix fits with our criteria for new clients. They have good management, strategy, products, services and increasing revenues. Their strategy to grow via acquisitions that provide healthcare services is a winner and are a job creator! The Eversull Group looks forward to providing our services to OCLG and working with their management."

Oncologix operates and manufactures Class II medical device products and delivers Personal Healthcare Services nationally. For its clients, Oncologix provides FDA approved medical devices and State licensed healthcare services. For its shareholders, Oncologix operates profitable business divisions that build, maintain and nourish shareholder value. The Company's corporate mission is to be the best small cap medical device and healthcare services holding company in North America.

This press release may contain forward-looking statements, made in reliance upon Section 21D of the Exchange Act of 1934, which involve known and unknown risks, uncertainties or other factors that could cause actual results to differ materially from the results, performance, or expectations implied by these forward-looking statements. The Company's expectations, among other things, are dependent upon economic conditions, continued demand for its products, the availability of raw materials, retention of its key management and operating personnel, its ability to operate its subsidiary companies effectively, need for and availability of more capital as well as other uncontrollable or unknown factors which are more fully disclosed in the Company's filings with the Securities and Exchange Commission.

CONTACT INFORMATION Wayne Erwin Chairman and CEO Email Contact (318) 769-1958 INVESTOR RELATIONS Jack Eversull President The Eversull Group, Inc. 972-571-1624 214-469-2361 fax Email Contact

Grafico Azioni Oncologix Tech (CE) (USOTC:OCLG)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni Oncologix Tech (CE) (USOTC:OCLG)
Storico
Da Giu 2023 a Giu 2024